Stocks & Investing
Stocks and Investing
Stocks and Investing
Tue, February 19, 2019
[ Tue, Feb 19th 2019
] - WOPRAI
[ Tue, Feb 19th 2019
] - WOPRAI
[ Tue, Feb 19th 2019
] - WOPRAI
Fri, February 15, 2019
[ Fri, Feb 15th 2019
] - WOPRAI
[ Fri, Feb 15th 2019
] - WOPRAI
[ Fri, Feb 15th 2019
] - WOPRAI
[ Fri, Feb 15th 2019
] - WOPRAI
[ Fri, Feb 15th 2019
] - WOPRAI
[ Fri, Feb 15th 2019
] - WOPRAI
Thu, February 14, 2019
[ Thu, Feb 14th 2019
] - WOPRAI
[ Thu, Feb 14th 2019
] - WOPRAI
[ Thu, Feb 14th 2019
] - WOPRAI
[ Thu, Feb 14th 2019
] - WOPRAI
[ Thu, Feb 14th 2019
] - WOPRAI
[ Thu, Feb 14th 2019
] - WOPRAI
[ Thu, Feb 14th 2019
] - WOPRAI
[ Thu, Feb 14th 2019
] - WOPRAI
[ Thu, Feb 14th 2019
] - WOPRAI
[ Thu, Feb 14th 2019
] - WOPRAI
[ Thu, Feb 14th 2019
] - WOPRAI
Vamil Divan Maintained (TEVA) at Hold with Decreased Target to $20 on, Feb 14th, 2019
Vamil Divan of Credit Suisse, Maintained "Teva Pharmaceutical Industries Limited" (TEVA) at Hold with Decreased Target from $26 to $20 on, Feb 14th, 2019.
Vamil has made no other calls on TEVA in the last 4 months.
There are 3 other peers that have a rating on TEVA. Out of the 3 peers that are also analyzing TEVA, 1 agrees with Vamil's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- David Amsellem of "Piper Sandler" Upgraded from Sell to Hold and Increased Target to $16 on, Wednesday, January 23rd, 2019
These are the ratings of the 2 analyists that currently disagree with Vamil
- Jason Gerberry of "B of A Securities" Upgraded from Sell to Strong Buy on, Thursday, January 3rd, 2019
- David Risinger of "Morgan Stanley" Upgraded from Hold to Buy and Held Target at $27 on, Monday, November 5th, 2018
